BioLineRx Announces Submission of New Drug Application (NDA) to FDA for Motixafortide in Stem Cell Mobilization

(marketscreener.com) Submission based on overwhelmingly positive top-line results from GENESIS Phase 3 study Stem cell mobilization for bone marrow transplantation estimated to be > $360 million market in the U.S. , with consistent growth TEL AVIV, Israel, Sept. 12, 2022 /PRNewswire/ -- BioLineRx Ltd. , a pre-commercial-stage biopharmaceutical company...https://www.marketscreener.com/quote/stock/BIOLINERX-LTD-61956566/news/BioLineRx-Announces-Submission-of-New-Drug-Application-NDA-to-FDA-for-Motixafortide-in-Stem-Cell-M-41750424/?utm_medium=RSS&utm_content=20220912